Delaware Court Orders Verisk to Complete $2.35 Billion AccuLynx Deal
Delaware judge rules Verisk must proceed with its $2.35 billion AccuLynx acquisition after the company tried to cancel the deal. Verisk plans to appeal.
/ 2 items
Delaware judge rules Verisk must proceed with its $2.35 billion AccuLynx acquisition after the company tried to cancel the deal. Verisk plans to appeal.
Charter (CHTR), Cognizant (CTSH), Insmed (INSM), Verisk (VRSK) and Zscaler (ZS) will be removed from the Nasdaq-100 Index effective June 22, 2026.